Skip to main content
Book cover

Targeted Therapies in Cancer:

Myth or Reality?

  • Book
  • © 2008

Overview

  • Presents findings from the 2005 meeting Targeted Therapies in Cancer: Myth or Reality
  • Reviews the move from empiricism to molecular targeted therapies and its effect on the development of new cancer therapies
  • Offers readers an overview of diverse approaches, ranging from drug discovery to cellular therapy
  • Includes supplementary material: sn.pub/extras

Part of the book series: Advances in Experimental Medicine and Biology (AEMB, volume 610)

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (13 chapters)

Keywords

About this book

In September 2005 an International Meeting on “Targeted Therapies in Cancer: Myth or Reality” was held in Milan. This successful Meeting was intended to represent a forum for scientists and clinicians working in cancer drug discovery and therapy to share their reflections and experiences on how the paradigm shift from empiricism to molecular targeted therapies is contributing to the translation of basic knowledge into new therapies for cancer patients. This book collects the contributions given by scientists and clinicians, from Academia and Industry, who participated to this Meeting.

We hope that this book contributes to improve our approach to cancer drug discovery and, ultimately, to find new, more efficacious and better tolerated drugs for cancer patients. It provides an overview of diverse approaches ranging from drug discovery to cellular therapy. Although this change in paradigm has been useful, its entry into the clinical arena was associates with unforeseen problems including the emergence of resistance, unexpected side effects and failures. Time is therefore ripe for a critical cultural reflection on the state of the art, prospects and limitations. Ultimately, is targeted therapy in cancer a myth or a reality?

Editors and Affiliations

  • Nerviano Medical Sciences, Nerviano (Milano), Italy

    Francesco Colotta

  • Istituto Clinico Humanitas and Institute of Pathology, University of Milan, Rozzano, Milano, Italy

    Alberto Mantovani

Bibliographic Information

Publish with us